Abstract
The exact impact of immune checkpoint inhibitors in the course and outcome of COVID-19 in cancer patients is currently unclear. Herein, we present the first description of an elderly melanoma patient who developed COVID-19 pneumonia while under treatment with nivolumab and bempegaldesleukin in combination with an investigational PEGylated interleukin (IL-2). We present the clinical characteristics and the laboratory and imaging findings of our patient during the course of COVID-19 pneumonia. Moreover, we discuss the currently available data regarding the mechanism of action of immune checkpoint inhibitors and IL-2 analogs in the treatment of COVID-19. The administration of these agents did not have a negative effect on the outcome of COVID-19 pneumonia in an elderly melanoma patient.
Keywords: COVID-19; bempegaldesleukin; case report; cytokines; immune-related pneumonitis; immunotherapy; melanoma; nivolumab.
【저자키워드】 COVID-19, Cytokines, Immunotherapy, Case report, Melanoma, bempegaldesleukin, immune-related pneumonitis, nivolumab., 【초록키워드】 Treatment, Clinical characteristics, Pneumonia, outcome, Laboratory, Patient, Immune checkpoint inhibitor, mechanism of action, IL-2, Combination, administration, cancer patient, nivolumab, available data, Course, 【제목키워드】 COVID-19 infection, clinical, Patient, nivolumab, Course, treated,